Comment re: Share Price Movement
Company clarifies NICE communication relates to NHS lab services, not point of care technology; funding under review.
Select text to share a quote on X · sign in to keep highlights & notes in your GDR notes
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the fall in the Company's share price on 13 August 2025 which it believes was connected to postings on the London South East Chat GDR Chat (https://www.lse.co.uk/ShareChat.html?ShareTicker=GDR) noting apparent communications from a member of staff at NICE with a member of the public.
The Company wishes to highlight that the apparent communication refers to services provided by NHS Genomic Services overseeing laboratory genomic testing and not point of care technologies. The funding position is being kept under active review as noted in the apparent communication.
Furthermore, whilst the Company is aware of the completion of the NHSE CYP2C19 pilot assessing logistics of deploying as a service at scale via laboratory or point of care, and what, based on interim assessment it anticipates to be a positive outcome supporting the role and impact of rapid CYP2C19 genetic testing in stroke patients, it has not yet been made aware of a publication date by NHSE and cannot confirm the dates reportedly conveyed in the communication.
Details of the interim assessment can be found:
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.